EUVIMEDEUVIMED entdecken
Crossref

Bayesian secondary reanalysis of published aggregate data on circulating tumor DNA for molecular residual disease detection across cancer types

Shugo Yajima iD, Soichiro Yoshida, Wei Chen, Hiroshi Fukushima, Hajime Tanaka, Hiroyuki Sato, Akihiro Hirakawa, Hitoshi Masuda, Yasuhisa Fujii

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · 23.07.2026

DOI: 10.1177/00045632261475618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, online erschienen am 23.07.2026. Verfasst von Shugo Yajima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Cancer Center Hospital East, Chiba, Japan. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing may help estimate recurrence risk after treatment. We performed a Bayesian secondary reanalysis of published aggregate data to estimate prognostic and diagnostic performance.

Methods

Data were extracted from Zheng et al. (80 studies, 11 cancer types). Log hazard ratios for recurrence were analyzed using Bayesian normal-normal hierarchical models. Sensitivity and specificity were analyzed using separate logit-scale random-effects models. Posterior probabilities were estimated from posterior samples.

Results

The prognostic analysis included 109 study arms (approximately 9,980 patients). The pooled hazard ratio for recurrence associated with ctDNA positivity was 7.5 (95% credible interval [CrI], 6.4-8.8). Among cancer-type subgroups reported separately, all 95% CrIs excluded 1.0. In 70 diagnostic studies, pooled sensitivity was 57.6% (95% CrI, 53.2-61.9) and specificity was 90.5% (95% CrI, 88.5-92.3). Longitudinal monitoring had higher sensitivity than landmark testing (73.6% vs 50.0%; posterior probability >99.9%), with similar specificity (89.9% vs 90.8%). mPCR-NGS had specificity of 93.2% (95% CrI, 90.2-95.6); in separate exploratory comparisons, P(mPCR-NGS > ddPCR) and P(mPCR-NGS > hybridization capture NGS) were both 96.0%.

Conclusions

This Bayesian secondary reanalysis supports the association between ctDNA-MRD positivity and recurrence risk. Longitudinal monitoring may improve sensitivity, while assay technology comparisons should be interpreted cautiously because they were based on aggregate, non-head-to-head data.

Schlagwörter

Stichwörter der Autor:innen

Circulating tumor DNAbayesian secondary reanalysisdiagnostic accuracylaboratory medicinemolecular residual diseaserecurrence

Autor:innen und Institutionen

  • Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Shugo Yajima

Zitieren

APA

Yajima, S., Yoshida, S., Chen, W., Fukushima, H., Tanaka, H., Sato, H., Hirakawa, A., Masuda, H., & Fujii, Y. (2026). Bayesian secondary reanalysis of published aggregate data on circulating tumor DNA for molecular residual disease detection across cancer types. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. https://doi.org/10.1177/00045632261475618

Vancouver

Yajima S, Yoshida S, Chen W, Fukushima H, Tanaka H, Sato H, et al. Bayesian secondary reanalysis of published aggregate data on circulating tumor DNA for molecular residual disease detection across cancer types. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2026. doi:10.1177/00045632261475618

BibTeX
@article{Yajima2026,
  author = {Yajima, Shugo and Yoshida, Soichiro and Chen, Wei and Fukushima, Hiroshi and Tanaka, Hajime and Sato, Hiroyuki and Hirakawa, Akihiro and Masuda, Hitoshi and Fujii, Yasuhisa},
  title = {Bayesian secondary reanalysis of published aggregate data on circulating tumor DNA for molecular residual disease detection across cancer types},
  journal = {Annals of Clinical Biochemistry: International Journal of Laboratory Medicine},
  year = {2026},
  doi = {10.1177/00045632261475618}
}
Kostenlos starten →